|
|
|
|
| LEADER |
01553 am a22002053u 4500 |
| 001 |
126231 |
| 042 |
|
|
|a dc
|
| 100 |
1 |
0 |
|a Ben-David, Uri
|e author
|
| 100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Biology
|e contributor
|
| 100 |
1 |
0 |
|a Koch Institute for Integrative Cancer Research at MIT
|e contributor
|
| 700 |
1 |
0 |
|a Amon, Angelika B
|e author
|
| 245 |
0 |
0 |
|a Context is everything: aneuploidy in cancer
|
| 260 |
|
|
|b Springer Science and Business Media LLC,
|c 2020-07-16T20:38:23Z.
|
| 856 |
|
|
|z Get fulltext
|u https://hdl.handle.net/1721.1/126231
|
| 520 |
|
|
|a Cancer is driven by multiple types of genetic alterations, which range in size from point mutations to whole-chromosome gains and losses, known as aneuploidy. Chromosome instability, the process that gives rise to aneuploidy, can promote tumorigenesis by increasing genetic heterogeneity and promoting tumour evolution. However, much less is known about how aneuploidy itself contributes to tumour formation and progression. Unlike some pan-cancer oncogenes and tumour suppressor genes that drive transformation in virtually all cell types and cellular contexts, aneuploidy is not a universal promoter of tumorigenesis. Instead, recent studies suggest that aneuploidy is a context-dependent, cancer-type-specific oncogenic event that may have clinical relevance as a prognostic marker and as a potential therapeutic target. ©2019, Springer Nature Limited.
|
| 520 |
|
|
|a NIH grant CA206157
|
| 520 |
|
|
|a NIH grant GM118066
|
| 546 |
|
|
|a en
|
| 655 |
7 |
|
|a Article
|
| 773 |
|
|
|t Nature Reviews Genetics
|
